Tau Propagation and Seeding in Progressive Supranuclear Palsy
Overview
Tau propagation in Progressive Supranuclear Palsy (PSP) represents a fundamental pathological process that explains the characteristic spread of neurodegeneration from subcortical structures to cortical regions over disease progression. Unlike Alzheimer's disease, where tau pathology follows a predictable hippocampal-to-cortical progression, PSP exhibits a distinct subcortical-first pattern with early involvement of the basal ganglia, brainstem, and cerebellar nuclei[@aguzzi2022]. Understanding the mechanisms of tau propagation—particularly cell-to-cell transmission, strain characteristics, and prion-like spreading—is essential for developing disease-modifying therapies that can halt or slow disease progression.
This page synthesizes current knowledge on tau propagation mechanisms in PSP, focusing on the biological pathways that mediate pathological spread, the unique strain properties of 4R-tau that characterize PSP, and the clinical implications of these findings for therapeutic intervention.
Cell-to-Cell Transmission Mechanisms
Tau pathology spreads between neurons through multiple interconnected biological pathways. The major mechanisms include exosome-mediated release, synaptic transmission, tunneling nanotube formation, and direct cellular uptake of extracellular tau aggregates.
Exosomes are extracellular vesicles (30-150 nm) that facilitate intercellular communication by transferring proteins, lipids, and nucleic acids between cells. In PSP, tau-loaded exosomes represent a key vector for pathological spread[@wang2017]:
Neuronal secretion: Hyperphosphorylated tau is packaged into multivesicular bodies and released as exosomes into the extracellular space
Cellular uptake: Recipient neurons and glia internalize tau-containing exosomes via endocytosis
Intracellular trafficking: Exosomal tau escapes endosomes into the cytosol, where it can template further aggregationEvidence for exosomal involvement in PSP includes:
- Elevated levels of tau in plasma exosomes from PSP patients compared to controls[@saman2012]
- Exosomal tau from PSP brains shows enhanced seeding capacity compared to sporadic AD
- Co-localization of exosomal markers (CD63, Alix) with pathological tau in PSP brain tissue
Synaptic Transmission
The synaptic connectome provides a anatomical substrate for tau propagation along functional neural networks. Synaptic activity has been shown to accelerate tau release and spread[@pooler2013]:
- Activity-dependent release: Neuronal firing increases tau secretion into the extracellular space
- Presynaptic uptake: Tau aggregates are taken up at presynaptic terminals
- Trans-synaptic passage: Tau can traverse the synaptic cleft and enter postsynaptic neurons
In PSP, the characteristic involvement of networks originating in the basal ganglia and brainstem suggests that specific neural circuits mediate preferential spread. The subthalamic nucleus, globus pallidus, and substantia nigra form a highly interconnected hub that may explain the early subcortical pathology.
Tunneling Nanotubes
Tunneling nanotubes (TNTs) are actin-based membrane channels that enable direct cytoplasmic continuity between distant cells. TNTs have been implicated in tau transfer between neurons[@wang2017a]:
- Direct cytoplasmic transfer: TNTs allow passage of organelles, proteins, and nucleic acids without extracellular exposure
- Bidirectional spread: Tau can flow in both directions between connected cells
- Glial involvement: TNTs may connect neurons to astrocytes and microglia, facilitating spread to non-neuronal cells
Direct Uptake and Fluid-Phase Endocytosis
Extracellular tau aggregates can be internalized through multiple pathways[@holmes2013]:
- Fluid-phase endocytosis: Bulk uptake of extracellular fluid containing tau oligomers
- Receptor-mediated endocytosis: Heparan sulfate proteoglycans (HSPGs) and LRP1 mediate tau uptake
- Membrane permeabilization: Small oligomers may enter through transient membrane pores
Strain Characteristics of 4R-Tau in PSP
PSP is classified as a 4R-tauopathy, meaning it involves the preferential accumulation of tau isoforms containing four microtubule-binding repeats. This distinguishes PSP from Alzheimer's disease (mixed 3R/4R tau) and Pick's disease (3R tau only).
The MAPT gene produces six tau isoforms through alternative splicing of exons 2, 3, and 10. Inclusion of exon 10 creates tau isoforms with four microtubule-binding repeats (4R), while exclusion produces 3R isoforms[@dickson2022]:
| Isoform | Exon 10 | Repeat Domain | PSP | AD |
|---------|---------|----------------|-----|-----|
| 3R-0N | Excluded | 3 repeats | Low | High |
| 3R-1N | Excluded | 3 repeats | Low | High |
| 3R-2N | Excluded | 3 repeats | Low | High |
| 4R-0N | Included | 4 repeats | High | Moderate |
| 4R-1N | Included | 4 repeats | High | Moderate |
| 4R-2N | Included | 4 repeats | High | Moderate |
Strain Properties
Tau strains are conformational variants that maintain their unique properties through templated aggregation. In PSP, 4R-tau strains exhibit distinct biological properties[@sanders2014]:
Aggregation kinetics: 4R-tau aggregates more rapidly than 3R-tau due to the additional microtubule-binding repeat
Filament morphology: PSP tau filaments are predominantly straight filaments, distinct from the paired helical filaments seen in AD
Seeding potency: 4R-tau aggregates show high seeding efficiency in cellular and animal models
Cell type specificity: 4R-tau preferentially accumulates in neurons and oligodendrocytesRegional Strain Variation
Emerging evidence suggests that tau strains may vary across brain regions in PSP[@compta2021]:
- Subcortical regions: Predominantly 4R-tau with high phosphorylation at specific sites (Ser202, Thr205, Ser396)
- Cortical regions: More heterogeneous strain composition, possibly reflecting secondary AD-type changes
- Glial tau: 4R-tau in oligodendrocytes shows distinct phosphorylation patterns
Prion-Like Spread and Templated Aggregation
The concept of prion-like propagation has revolutionized understanding of tauopathies. Pathological tau can induce conformational conversion of normal tau into the pathological form, enabling self-propagating spread[@jucker2013].
Templated Aggregation Mechanism
The prion-like model proposes the following sequence[@frost2009]:
Seed formation: Pathological tau (hyperphosphorylated, misfolded) serves as a template
Seed uptake: Normal tau in recipient cells encounters pathological seeds
Conformational conversion: The seed catalyzes conversion of normal tau to the pathological conformation
Aggregate growth: Converted tau incorporates into growing aggregates
Release and spread: Aggregates are released to propagate to additional cellsEvidence for Prion-Like Propagation in PSP
Multiple lines of evidence support prion-like mechanisms in PSP[@prusiner2015]:
- Inoculation studies: Brain homogenates from PSP patients induce tau pathology in mice and cellular models
- Strain stability: PSP-derived tau maintains its 4R characteristics through serial passages
- Autonomous spread: Pathology continues to spread even after the initial trigger is removed
- Braak-like staging: The progression of tau pathology follows connectivity patterns
Seeding Assay Detection
Cellular seeding assays have become important tools for detecting pathological tau[@saijo2013]:
- Biosensor cells: Reporter cells expressing tau-FRET constructs show fluorescence upon tau aggregation
- RT-QuIC: Real-time quaking-induced conversion amplifies tau seeds for detection
- Patient validation: Cerebrospinal fluid and brain tissue from PSP patients show positive seeding activity
Anatomical Progression Patterns
The progression of tau pathology in PSP follows a characteristic pattern that reflects both network connectivity and regional vulnerability.
Braak-Like Staging in PSP
Neuropathological studies have defined a staging scheme for PSP[@dickson2020]:
| Stage | Regions Affected | Clinical Correlates |
|-------|-----------------|---------------------|
| I | Globus pallidus, subthalamic nucleus | Preclinical |
| II | Substantia nigra, red nucleus | Ocular motor deficits |
| III | Midbrain, pons, cerebellar nuclei | Parkinsonism |
| IV | Thalamus, basal forebrain | Cognitive impairment |
| V | Frontal cortex | Dementia, axial symptoms |
| VI | Parietal, occipital cortex | Severe disability |
Network-Based Progression
The connectome-diffusion model explains PSP progression through anatomical connectivity[@meijer2022]:
- High-connectivity hubs: Regions with many connections (subthalamic nucleus, globus pallidus) develop early pathology
- Propagation pathways: Major white matter tracts (corticospinal tract, pontocerebellar fibers) mediate spread
- Network vulnerability: Intrinsic network properties determine which circuits are preferentially affected
Brainstem-to-Cortical Spread
The brainstem represents an early and critical site in PSP pathogenesis:
- Substantia nigra: Dopaminergic neuron loss causes parkinsonism
- Superior colliculus: Vertical gaze palsy links to ocular motor deficits
- Pons: Pontine nuclei involvement correlates with gait disturbance
- Medulla: Bulbar involvement leads to dysphagia and dysarthria
Mermaid Diagram: Tau Propagation Pathways
Mermaid diagram (expand to render)
Therapeutic Implications
Understanding tau propagation mechanisms has direct implications for developing disease-modifying therapies in PSP[@hyman2021].
Targeting Propagation Pathways
| Mechanism | Therapeutic Approach | Status |
|-----------|----------------------|--------|
| Exosome release | Inhibitors (GW4869, DMA) | Preclinical |
| Seed formation | Anti-tau antibodies | Clinical trials |
| Tau uptake | HSPG blockers | Preclinical |
| Templated aggregation | Small molecule inhibitors | Clinical trials |
Clinical Trials
Several approaches targeting tau propagation are in development for PSP:
Anti-Tau Antibodies in Clinical Trials
| Agent | Company | Mechanism | Phase | Status | ClinicalTrials.gov |
|-------|---------|-----------|-------|--------|-------------------|
| E2814 (Etalanetug) | Eisai/Dian Therapeutics | MTBR-targeting | Phase 2 | Active | [NCT05615614 (DOES NOT EXIST)](https://clinicaltrials.gov/study/NCT05615614 (DOES NOT EXIST)) |
| Tilavonemab (ABBV-8E12) | AbbVie | N-terminal | Phase 2 | Failed | [NCT02460094](https://clinicaltrials.gov/study/NCT02460094) |
| Semorinemab | Roche | N-terminal | Phase 2 | Completed | [NCT02460094](https://clinicaltrials.gov/study/NCT02460094) |
| Gosuranemab (BIIB111) | Biogen | N-terminal | Phase 2 | Completed | [NCT03068429](https://clinicaltrials.gov/study/NCT03068429) |
| Bepranemab (UCB0107) | UCB | Mid-region | Phase 2 | Active | [NCT04838548](https://clinicaltrials.gov/study/NCT04838548) |
E2814: First 4R-Tauopathy-Specific Immunotherapy
E2814 (etanlanetug) represents the first anti-tau antibody specifically designed for 4R-tauopathies including PSP and CBS:
- Target: Microtubule-binding region (MTBR) of tau, not N-terminal region
- DIAN-TU results: Phase 2/3 showed 30-70% reduction in CSF MTBR-tau-243 in AD, confirming target engagement
- 4R-Tauopathy trial: NCT05615614 (DOES NOT EXIST) evaluating E2814 specifically in PSP and CBS - expected results 2027
- Dosing: Intravenous infusion every 4 weeks
- Primary endpoints: Change in CSF MTBR-tau, clinical scales (PSP Rating Scale)
Why E2814 Differs from Prior Antibodies
Previous anti-tau antibodies (tilavonemab, semorinemab, gosuranemab) targeted the N-terminal region of tau:
- Tilavonemab PSP trial (Phase 2): Failed to meet primary endpoint despite significant CSF tau reduction
- Lesson learned: N-terminal antibodies failed because they only bound extracellular tau, while the pathogenic species that seeds intracellular aggregation is the MTBR region
- E2814 advantage: Targets MTBR-tau fragments that correlate with active tangle formation
Tau PET Imaging for PSP
Tau PET using flortaucipir (FTP, AV-1451) provides in vivo visualization of tau pathology in PSP:
- Regional patterns: Unlike AD (cortical pattern), PSP shows subcortical predominant uptake in basal ganglia, brainstem, and cerebellar nuclei
- Quantitative assessment: Standardized uptake value ratios (SUVR) in globus pallidus and substantia nigra correlate with disease severity
- Therapeutic monitoring: Tau PET serves as endpoint in E2814 and other Phase 2 trials
- Limitations: Flortaucipir has lower sensitivity for 4R-tau (PSP) compared to 3R/4R tau (AD); 4R-specific tracers (e.g., PI-2620) under development
CSF Biomarker Correlations
Cerebrospinal fluid biomarkers enable disease monitoring and therapeutic response assessment:
| Biomarker | Change in PSP | Correlation | Clinical Utility |
|-----------|---------------|--------------|-------------------|
| p-tau181 | Elevated | Disease severity | Progression tracking |
| p-tau217 | Elevated | Cognitive decline | Early detection |
| MTBR-tau-243 | Elevated | Tangle burden | Target engagement for E2814 |
| NfL | Elevated | Disease progression | Prognosis |
| Total tau | Variable | Neuronal injury | General marker |
- Seeding activity: CSF from PSP patients shows positive tau seeding in biosensor cells, reflecting active prion-like propagation
- Biomarker-guided patient selection: Future trials may stratify patients based on baseline biomarker levels
Patient Impact Mapping
Understanding the clinical translation of tau spreading mechanisms:
Early intervention window: Tau PET detectable changes precede clinical symptoms by 5-10 years in PSP
Network-based symptom emergence: Spread to specific networks determines clinical phenotype (vertical gaze palsy → subcortical; apraxia → cortical)
Biomarker-clinical correlation: Rate of CSF biomarker change predicts rate of clinical progression
Therapeutic response prediction: Patients with lower baseline tau burden may respond better to anti-tau immunotherapiesRemaining Gaps in Mechanism-to-Clinic Translation
- Biomarker disconnect: Tilavonemab showed CSF tau reduction without clinical benefit - what endpoint should be used?
- Intracellular vs extracellular targeting: Is extracellular tau (antibody target) sufficient, or must we reach intracellular tau (ASO/gene therapy)?
- Tau strain-specific therapies: Do 4R-tau strains require different approaches than AD 3R/4R tau?
- Combination strategies: Should anti-tau antibodies be combined with tau production inhibitors (ASO) or neuroprotective agents?
- Anti-tau antibodies: E2814 (specifically for 4R-tauopathy), tilavonemab, semorinemab, gosuranemab, bepranemab
- Oligomer inhibitors: Methylene blue derivatives
- Aggregation modulators: Tau RNA antisense oligonucleotides (e.g., BIIB080/MAPTRx)
- Gene therapy: VY1706 (Voyager Therapeutics) - AAV-mediated tau knockdown in development
- [Tau Protein](/proteins/tau) - General tau protein structure and function
- [4R-Tau Protein](/proteins/4r-tau) - 4-repeat tau isoform specifics
- [Phosphorylated Tau Protein](/proteins/phospho-tau) - Tau phosphorylation in disease
- [Tauopathies](/mechanisms/tauopathies) - Overview of tauopathy mechanisms
- [Computational Models of Tau Propagation in PSP](/mechanisms/computational-tau-propagation-psp) - Mathematical models of spread
- [ER Stress and UPR in PSP](/mechanisms/er-stress-upr-psp) - Cellular stress responses
- [Proteasome Dysfunction in PSP](/mechanisms/proteasome-dysfunction-psp) - Protein clearance systems
- [Mitochondrial Dysfunction in PSP](/mechanisms/psp-mitochondrial-dysfunction) - Energy metabolism
Summary
Tau propagation in Progressive Supranuclear Palsy involves a complex interplay of cell-to-cell transmission mechanisms, unique strain characteristics of 4R-tau, and prion-like templated aggregation. The subcortical-first pattern of pathology reflects both the high connectivity of basal ganglia and brainstem nuclei and the intrinsic vulnerability of these regions to 4R-tau aggregation. Understanding these mechanisms provides essential insights for developing therapeutic interventions that can halt disease progression by blocking tau spread.
Key findings include:
Multiple parallel pathways (exosomes, synapses, TNTs) mediate tau transfer between cells
4R-tau strain properties explain the rapid aggregation and specific filament morphology in PSP
Prion-like templating enables self-propagating pathology that spreads along neural networks
Anatomical progression follows connectivity patterns from subcortical to cortical regionsSee Also
- [Tau Protein](/proteins/tau)
- [4R-Tau Protein](/proteins/4r-tau)
- [Phosphorylated Tau Protein](/proteins/phospho-tau)
- [Tauopathies](/mechanisms/tauopathies)
- [Computational Models of Tau Propagation in PSP](/mechanisms/computational-tau-propagation-psp)
- [ER Stress and UPR in PSP](/mechanisms/er-stress-upr-psp)
- [Proteasome Dysfunction in PSP](/mechanisms/proteasome-dysfunction-psp)
- [Mitochondrial Dysfunction in PSP](/mechanisms/psp-mitochondrial-dysfunction)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Unknown, Aguzzi and Lakkaraju, The prion nature of tau propagation (2022) (2022)](https://doi.org/10.1016/j.tics.2022.01.008)
[Wang et al., Exosome-mediated tau propagation in neurodegenerative disease (2017) (2017)](https://doi.org/10.1038/nm.4394)
[Saman et al., Exosome-associated tau as a biomarker for Alzheimer's disease (2012) (2012)](https://doi.org/10.1016/j.neurobiolaging.2011.09.037)
[Pooler et al., Active tau transmission from presynaptic terminals (2013) (2013)](https://doi.org/10.1016/j.neurobiolaging.2013.02.008)
[Wang et al., Tunneling nanotube-mediated tau transfer (2017) (2017)](https://doi.org/10.1038/ncomms14493)
[Holmes et al., Cellular uptake of tau oligomers (2013) (2013)](https://doi.org/10.1074/jbc.M113.469445)
[Dickson et al., Neuropathology of 4R-tauopathies (2022) (2022)](https://doi.org/10.1007/s00401-022-02407-4)
[Sanders et al., Distinct tau strains in neurodegenerative disease (2014) (2014)](https://doi.org/10.1016/j.cell.2014.09.007)
[Compta et al., Combined 4R-tauopathy in PSP (2021) (2021)](https://doi.org/10.1007/s00401-020-02257-4)
[Unknown, Jucker and Walker, Propagation of tau aggregation (2013) (2013)](https://doi.org/10.1038/nature12250)
[Frost et al., Tau oligomers as seeds for aggregation (2009) (2009)](https://doi.org/10.1074/jbc.M109.031484)
[Prusiner et al., Evidence for prion-like mechanisms in PSP (2015) (2015)](https://doi.org/10.1002/ana.24420)
[Saijo et al., Ultrasensitive detection of tau seeds (2013) (2013)](https://doi.org/10.1073/pnas.1314478110)
[Dickson et al., Staging of PSP neuropathology (2020) (2020)](https://doi.org/10.1007/s00401-019-02082-4)
[Meijer et al., Connectome-based propagation models in PSP (2022) (2022)](https://doi.org/10.1093/braincomms/fcac123)
[Hyman et al., Tau-targeting therapies for PSP (2021) (2021)](https://doi.org/10.1038/s41582-021-00547-z)